



17th INTERNATIONAL
CONFERENCE
ON BEHÇET'S DISEASE

MATERA
15th - 17th SEPTEMBER 2016



● | TABLE OF CONTENTS

WELCOME MESSAGE	5
COMMITTEES	7
ICBD 2016 PROGRAMME	8
POSTER PRESENTATION INDEX	20
INTERNATIONAL PATIENTS' CONFERENCE - MATERA 2016	24
SOCIAL PROGRAMME	26

GENERAL INFORMATION

Conference Venue

Casa di Spiritualità Sant'Anna

Via Lanera 14

75100 Matera - Italy

Date of Conference

15-17 September 2016

Official Website

www.allmeetingsmatera.it/behcets/

Language

The language of the Conference is English.

No translation services will be provided.

Name Badge

All participants must put on their Name Badges at entry

to the congress centre, during scientific sessions,

in exhibition halls and during other social activities.



● | WELCOME MESSAGE

Dear Friends and Colleagues,

Welcome to the 17th International Conference on Behçet's Disease in Matera organized under the auspices of the International Society for Behçet's Disease.

The venue of the Conference is the Sant'Anna Congress Center which is ten minutes walk from the old city of Matera.

The Conference Steering Committee has planned to provide an excellent scientific programme covering all topics of Behçet's Disease aiming at bridging new development in basic and clinical science. There will be the "Meet the Expert" breakfast session, inaugurated in the Paris 16th Conference, which will give the opportunity especially to young doctors to share experiences with the experts.

There will also be a one-day meeting for patients and families which has been prepared together with the patients' associations, Behçet's International and the Italian SIMBA.

You are cordially invited to the Welcome Cocktail and Concert on Thursday 15th September and to the Social Dinner on Friday 16th September (on registration only). Tours will be available for the accompanying persons.

Matera is one of the most singular and interesting cities of Italy. Matera is internationally famous for its two extensive and ancient neighbourhoods of stone and cave dwelling, known as Sassi, that are among the oldest continuously-inhabited settlements in history. A walk through Sassi will transport you back into a past long-forgotten. In 2014, Matera was declared Italian host of European Capital of Culture for 2019.

I wish you an outstanding meeting and an unforgettable stay in my city.

Ignazio Olivieri

President of the 17th International Conference on Behçet's Disease



PRESIDENT OF CONGRESS

Ignazio OLIVIERI

HONORARY PRESIDENT

Carlo SALVARANI

EXECUTIVE COMMITTEE – INTERNATIONAL SOCIETY FOR BEHÇET’S DISEASE (ISBD)

President	Shigeaki OHNO	Japan - Ophthalmology
Past-President	Sungnack LEE	Korea - Dermatology
Secretary	Ahmet GÜL	Turkey - Dermatology
Treasurer	Michael SCHIRMER	Austria - Internal Medicine
Vice-President	Dorian HASKARD	UK - Rheumatology
President Past International Congress	Isabelle KONE-PAUT	France - Paediatrics
Member – Dermatology	Christos ZOUBOULIS	Germany - Dermatology
Member – Ophthalmology	Miles STANDFORD	UK - Ophthalmology
Member – Scientific Affairs	Farida FORTUNE	UK - Oral Health
Member – Publications Affairs	Yusuf YAZICI	USA - Rheumatology
President of 17th International Congress	Ignazio OLIVIERI	Italy - Rheumatology

HONORARY LIFE PRESIDENTS – INTERNATIONAL SOCIETY FOR BEHÇET’S DISEASE (ISBD)

Colin G. BARNES	UK - Rheumatology
Nihat DILSEN	Turkey - Rheumatology
Thomas LEHNER	UK - Rheumatology
Desmond O’DUFFY	USA - Rheumatology
Hasan YAZICI	Turkey - Rheumatology

LOCAL REGIONAL ORGANIZING COMMITTEE

Ignazio OLIVIERI	Italy - Rheumatology
Michele GILIO	Italy - Rheumatology
Angela PADULA	Italy - Rheumatology
Gabriella CONIGLIO	Italy - Neurology
Pietro LECCESE	Italy - Rheumatology
Carlo PALAZZI	Italy - Rheumatology
Salvatore D’ANGELO	Italy - Rheumatology
Loredana LATANZA	Italy - Ophthalmology

● | I CBD 2016 PROGRAMME

14th September 2016, Wednesday

- 16:00 - 17:00 Executive Committee Meeting
17:00 - 18:30 Council Meeting
19:30 - 22:30 President's Dinner

15th September 2016, Thursday

- 7:55 - 8:25 Registration
8:25 - 9:00 President's Welcome Speech
ISBD Honorary Life President's Speech
9:00 - 9:45 **Special Lecture**
Chairs: Ignazio Olivieri (Italy), Carlo Salvarani (Italy)
BEHÇET'S DISEASE IN THE 2000s
Hasan Yazici (Turkey)
9:45 - 11:15 **Scientific Session 1: Basic Science**
Chairs: Farida Fortune (UK), David Saadoun (France)
9:45 - 10:05 **CYTOKINES AND INTRA-CELLULAR MECHANISM OF INFLAMMATION**
Graham Wallace (UK)
10:05 - 10:25 **IMMUNE RESPONSE AND TISSUE-SPECIFIC FACTORS**
Haner Direskeneli (Turkey)
10:25 - 10:45 **INFLAMMATION AND VASCULAR THROMBOSIS**
Lorenzo Emmi (Italy)

10:45 - 11:15

Oral Presentations

Chairs: Jan Van Laar (Netherlands), Fabrizio Conti (Italy)

01) SERUM CYTOKINE PROFILE IN PATIENTS WITH BEHÇET'S DISEASE
Orso Maria Lucherini¹, Giuseppe Lopalco², Luca Cantarini¹, Antonio Lopalco³, Vincenzo Venerito², Marco Fornaro², Antonio Vitale¹, Giacomo Emmi⁴, Giovanni Lapadula², Florenzo Iannone²

¹University of Siena, Department of Medical Sciences, Surgery and Neuroscience, Siena, Italy, ²University of Bari, Interdisciplinary Department of Medicine, Bari, Italy, ³University of Kansas, Lawrence, Kansas (USA), ⁴University of Florence, Florence, Italy

02) OCULAR DISEASE PHENOTYPING FROM MULTIPARAMETER CELL ANALYSIS BY MACHINE LEARNING ALGORITHMS
Graham Wallace¹, Julian Candia², Laura Morton¹, Angelique Biancotta², Philip Murray¹, Robert Nussenblatt²

¹University of Birmingham, Institute of Inflammation and Ageing, Birmingham, UK, ²National Institutes of Health, Bethesda, Maryland (USA)

03) EXPRESSION OF HOMING MARKERS ON PERIPHERAL BLOOD LYMPHOCYTES IN BEHÇET'S DISEASE PATIENTS AND HEALTHY CONTROLS
Lesley Ann Bergmeier, Adeel Malik, Najlae Boukbir, Samiul Hasan, Farida Fortune
Queen Mary University of London, Centre for Clinical and Diagnostic Oral Sciences, Institute of Dentistry, London, UK

11:15 - 11:45 Coffee Break

11:45 - 13:15

Scientific Session 2: Epidemiology & Genetics

Chairs: Graham Wallace (UK), Mauro Galeazzi (Italy)

11:45 - 12:05

GENETIC CONTRIBUTION TO THE PHENOTYPE OF BEHÇET'S DISEASE

Ahmet Gül (Turkey)

12:05 - 12:25

BEHÇET'S DISEASE WORLDWIDE: IS IT THE SAME DISEASE?

Alfred Mahr (France)

12:25 - 12:45

CRITERIA AND THE DEFINITION OF DISEASE

Hasan Yazici (Turkey)



● | I CBD 2016 PROGRAMME

12:45 - 13:15

Oral Presentations

Chairman: Jorge Crespo (Portugal), Wafa Madanat (Jordan)

04) DENSE GENOTYPING OF IMMUNE-RELATED LOCI IMPLICATES HOST RESPONSES TO MICROBIAL EXPOSURE IN BEHÇET'S DISEASE SUSCEPTIBILITY

Masaki Takeuchi¹, Nobuhisa Mizuki², Akira Meguro², Michael Ombrello³, Yohei Kirino², Colleen Satorius¹, Julie Le¹, Burak Erer⁴, Tatsukata Kawagoe², Duran Ustek⁵, Ilknur Tugal-Tutkun⁴, Emire Seyahi⁶, Yilmaz Ozyazgan⁶, Inês Sousa⁷, Fereydoun Davatchi⁸, Vânia Francisco⁷, Farhad Shahram⁸, Bahar Abdollahi⁸, Abdolhadi Nadji⁸, Nilofar Shafiee⁸, Fahmida Ghaderibarmi⁸, Shigeaki Ohno⁹, Atsuhisa Ueda², Yoshiaki Ishigatsubo², Sofia Oliveira⁷, Ahmet Gül⁴, Daniel Kastner¹⁰, Elaine Remmers¹⁰

¹National Human Genome Research Institute, Inflammatory Disease Section, Bethesda, USA, ²Yokohama City University Graduate School of Medicine, Yokohama City, Japan, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, USA, ⁴Istanbul Faculty of Medicine, Istanbul University, Turkey, ⁵nstitute Institute for Experimental Medicine, Istanbul University, Turkey, ⁶Cerrahpasa Faculty of Medicine, Istanbul University, Turkey, ⁷Faculdade de Medicina, Universidade de Lisboa, Portugal, ⁸Tehran University of Medical Sciences, Tehran, Iran, ⁹Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ¹⁰National Institutes of Health, Bethesda, USA

05) GENOME-WIDE SCREENING OF LOCI ASSOCIATED WITH CLINICAL MANIFESTATIONS OF BEHÇET'S DISEASE

Takahiro Yamane¹, Akira Meguro¹, Masaki Takeuchi², Shigeaki Ohno³, Nobuhisa Mizuki¹

¹Yokohama City University Graduate School of Medicine, Department of Ophthalmology and Visual Science, Yokohama City, Japan

06) HOMOZYGOSITY FOR A SINGLE ERAP1 ALLOTYPE GREATLY INCREASES BEHCET'S DISEASE RISK IN HLA-B*51 CARRIERS

Elaine F. Remmers¹, Masaki Takeuchi¹, Michael J. Ombrello², Yohei Kirino³, Burak Erer⁴, Ilknur Tugal-Tutkun⁴, Emire Seyahi⁵, Yilmaz Özyazgan⁵, Norman R. Watts², Ahmet Gül⁴, Daniel L. Katner¹

¹National Human Genome Research Institute, Inflammatory Disease Section, Bethesda, USA, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, USA, ³Yokohama City University Graduate School of Medicine, Yokohama City, Japan, ⁴Istanbul Faculty of Medicine, Istanbul University, Turkey, ⁵Cerrahpasa Faculty of Medicine, Istanbul University, Turkey

13:15 - 14:30

Lunch

14:30 - 15:30

Poster Session

15:30 - 17:00

Scientific Session 3: Vascular Disease

Chairs: Carlo Salvarani (Italy), Michael Schirmer (Austria)

15:30 - 15:50

VASCULAR MANIFESTATIONS - A CLINICAL OVERVIEW

Kenneth Calamia (USA)

15:50 - 16:10

VASCULAR IMAGING AND VESSEL WALL CHANGES

Dorian Haskard (UK)

16:10 - 16:30

PULMONARY VASCULAR DISEASE

Emire Seyahi (Turkey)

16:30 - 17:00

Oral Presentations

Chairman: Samir Assaad Khalil (Egypt), Melike Melikoglu (Turkey)

07) POST-THROMBOTIC SYNDROME IS INCREASED AND VENOUS DISEASE SPECIFIC QUALITY OF LIFE IS IMPAIRED IN PATIENTS WITH VASCULAR BEHÇET'S DISEASE WITH NO BENEFIT OF ANTICOAGULANT USE

Fatma Alibaz Oner¹, Belgin Aldag¹, Mustafa Aldag², Ali Ugur Unal¹, Aydan Mutis¹, Tayfur Toptas³, Tulin Ergun⁴, Haner Direskeneli¹

¹Marmara University, School of Medicine, Department of Rheumatology, Istanbul, Turkey, ²Siyami Ersek Cardiyovascular Surgery Research and Education Hospital, Istanbul, Turkey, ³Marmara University, School of Medicine, Department of Hematology, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey

08) AN OUTCOME SURVEY OF 100 PATIENTS WITH CEREBRAL VENOUS SINUS THROMBOSIS DUE TO BEHÇET'S SYNDROME FOLLOWED UP AT A SINGLE, DEDICATED CENTER

Enes Ali Kurt¹, Naci Kocer², Yesim Ozguler¹, Didar Ucar³, Ugur Uygunoglu⁴, Civan Islak², Sebahattin Saip⁴, Melike Melikoglu¹, Vedat Hamuryudan¹, Yilmaz Ozyazgan³, Sebahattin Yurdakul¹, Aksel Siva⁴, Hasan Yazici¹, Emire Seyahi¹

¹Cerrahpasa Faculty of Medicine, Department Of Internal Medicine, Division of Rheumatology, Istanbul University, Turkey, ²Cerrahpasa Faculty of Medicine, Department Of Radiology, Istanbul University, Turkey, ³Cerrahpasa Faculty of Medicine, Department Of Ophthalmology, Istanbul University, Turkey, ⁴Cerrahpasa Faculty of Medicine, Department Of Neurology, Istanbul University, Turkey

09) A LOW BALANCE BETWEEN MICROPARTICLES EXPRESSING TISSUE FACTOR PATHWAY INHIBITOR AND TISSUE FACTOR IS ASSOCIATED WITH THROMBOSIS IN BEHÇET'S SYNDROME

Emon Khan¹, Nicky Ambrose¹, Josefin Ahnström¹, Allan Kiprianos¹, Miles Stanford², Despina Eleftheriou³, Paul Brogan³, Justin Mason¹, Michael Johns¹, Mike Laffan¹, Dorian Haskard¹

¹Imperial College London, NHLI Department, London, UK, ²King's College London, London, UK, ³University College London, London, UK

17:00 - 18:00

General Assembly

18:00 - 19:00

Welcome Cocktail

● | I CBD 2016 PROGRAMME

16th September 2016, Friday

- 8:00 - 9:00 **“Meet the Expert” Breakfast Session (see details on page 18)**
- 9:00-10:30 **Scientific Session 4: Ocular Behçet’s Disease**
Chairs: Shigeaki Ohno (Japan), Miles Stanford (UK)
- 9:00 - 9:20 **DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS**
Iknur Tugal-Tutkun (Turkey)
- 9:20 - 9:40 **TREATMENT IN THE BIOLOGIC ERA**
Kenichi Namba (Japan)
- 9:40 - 10:00 **UNMET NEEDS**
Moncef Khairallah (Tunisia)
- 10:00 - 10:30 **Oral Presentations**
Chairs: Massimo Accorinti (Italy), Loredana Latanza (Italy)
- 010) EARLIER USE OF INFLIXIMAB FOR THE UVEITIS OF BEHÇET’S SYNDROME APPEARS TO BE ASSOCIATED WITH BETTER OUTCOME**
Gul Guzelant, Didar Ucar, Gulen Hatemi, Yilmaz Ozyazgan, Sinem Nihal Esatoglu, Sebahattin Yurdakul, Emire Seyahi, Hasan Yazici, Vedat Hamuryudan
Cerrahpasa Faculty of Medicine, Rheumatology Department, Istanbul University, Turkey
- 011) EVALUATION OF OCULAR DISEASE ACTIVITY USING BEHÇET’S DISEASE OCULAR ATTACK SCORE 24**
Tatiana Lisitsyna¹, Galina Davydova², Zalina Khatagova², Ludmila Katargina², Zemfira Alekberova¹, Evgeny Nasonov¹
¹Nasonova Research Institute of Rheumatology, Systemic Rheumatic Diseases, Moskow, Russia
²Moscow Helmholtz Research Institute of Eye Diseases, Moskow, Russia.
- 012) CELLULAR IMMUNE RESPONSES IN BEHÇET’S DISEASE PATIENTS WITH UVEITIS DURING INFLIXIMAB TREATMENT**
Masaru Takeuchi, Yoko Karasawa, Kohzou Harimoto, Yutaka Sakurai, Tomohito Sato, Rachel Caspi, Masataka Ito
National Defense Medical College, Ophthalmology Department, Saitama, Japan
- 10:30 - 11:00 Coffee Break
- 11:00 -12:30 **Scientific Session 5: Neuro-Behçet’s Disease**
Chairs: Adnan Al-Araji (UK), Fabrizio Salvi (Italy)
- 11:00 - 11:20 **HISTORY, EPIDEMIOLOGY AND CLINICAL FEATURES**
Afshin Borhani-Haghighi (Iran)

- 11.20 - 11:40 **DIAGNOSIS AND TREATMENT**
Gulsen Akmar-Demir (Turkey)
- 11:40 - 12:00 **CLINICAL CASES**
Adnan Al-Araji (UK)
- 12:00 - 12:30 **Oral Presentations**
Chairs: Gabriella Coniglio (Italy), Habib Houman (Tunisia)
- 013) COGNITIVE IMPAIRMENT IN CHRONIC PROGRESSIVE NEURO- BEHÇET’S DISEASE: COMPARATIVE STUDY OF BRAINSTEM AND HIPPOCAMPUS REGION USING BRAIN MAGNETIC RESONANCE IMAGING**
Hirotoshi Kikuchi¹, Kurumi Asako¹, Hajime Kono¹, Shunsei Hirohata²
¹Teikyo University School of Medicine, Internal Medicine Department, Tokyo, Japan, ²Kitasato University School of Medicine, Tokyo, Japan
- 014) BEHCET’S SYNDROME AND PSYCHIATRIC INVOLVEMENT: IS IT A PRIMARY OR SECONDARY FEATURE OF THE DISEASE?**
Rosaria Talarico¹, Elena Elefante¹, Laura Palagini²
¹University of Pisa, Department of Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy,
²University of Pisa, Department of Clinical and Experimental Medicine, Psychiatric Unit, Pisa, Italy
- 015) THE COCHLEAR INVOLVEMENT IN BEHÇET’S DISEASE: CROSS SECTIONAL STUDY**
Klii Rim, Maateur Houda, Kechida Melek, Chaaben Imen
Fattouma Bourguiba Hospital, Internal Medicine, Monastir, Tunisia
- 12:30 - 13:20 **Scientific Session 6: Locomotor System Disease**
Chairs: Saida Benamour (Morocco), Yoshiaki Ishigatsubo (Japan)
- 12:30 - 12:50 **MUSCULOSKELETAL MANIFESTATIONS – A CLINICAL OVERVIEW**
Fereydoun Davatchi (Iran)
- 12:50 - 13:10 **BEHÇET’S DISEASE AND SPONDYLOARTHRITIS**
Ignazio Olivieri (Italy)
- 13:10 - 13:20 **Oral Presentation**
Chairman: Raffaele Scarpa (Italy)
- 016) PREDICTIVE VALUE OF BONE SCINTIGRAPHY FOR THE DETECTION OF JOINT INVOLVEMENT IN BEHÇET’S DISEASE: DERMATOLOGISTS’ PERSPECTIVES**
Jimyung Seo¹, Minseok Lee¹, Zhenlong Zheng¹, Arthur Cho¹, Haryeong Ryu², Dongsik Bang³
¹Yonsei University College of Medicine, Department of Dermatology and Cutaneous Biology Research Institute, Seoul, Korea, ²Gil Medical Center, Gachon University, Seongnam, Korea, ³Catholic Kwandong University, International St. Mary’s Hospital, Gangneung, Gangwon-do, Korea

● | ICB D 2016 PROGRAMME

13:20 – 14:30	Lunch
14:30 - 15:30	Poster Session
15:30 - 17:00	Scientific Session 7: Mucocutaneous Disease <i>Chairs: Sungnack Lee (Korea), Dongsik Bang (Korea), Christos C. Zouboulis (Germany)</i>
15:30 - 15:50	THE SIGNIFICANCE OF MUCOCUTANEOUS MANIFESTATIONS Eun-So Lee (Korea)
15:50 - 16:20	DIAGNOSTIC ASPECTS OF MUCOCUTANEOUS MANIFESTATIONS Erkan Alpsoy (Turkey)
16:20 - 16:40	THERAPEUTIC ASPECTS OF MUCOCUTANEOUS MANIFESTATIONS Andreas Altenburg (Germany)
16:40 - 17:00	Oral Presentations
	017) DIETARY AND NON-DIETARY TRIGGERS OF ORAL ULCER RECURRENCES IN BEHÇET'S DISEASE Geoffroy Volle ¹ , Jean-Baptiste Fraison ² , Aurélie Thuillier ¹ , Robin Dhote ³ , Delphine Gobert ⁴ , Tiphaine Goulenok ⁵ , François Lhote ⁶ , Sophie Rivière ⁷ , Alfred Mahr ¹ ¹ Hospital Saint-Louis, Internal Medicine Department, Paris, France, ² Hospital Jean-Verdier, Bondy, France, ³ Hospital Avicenna, Bobigny, France, ⁴ Hospital Saint-Antoine, Paris, France, ⁵ Hospital Bichat, Paris, France, ⁶ Hospital Delafontaine, Saint-Denis, France, ⁷ Hospital Saint-Eloi, Montpellier, France
	018) ORAL HEALTH CAN BE IMPROVED BY ORAL HYGIENE EDUCATION IN BEHCET'S DISEASE: A LONG-TERM FOLLOW-UP STUDY Gonca Mumcu ¹ , Ugur Alpar ² , Nevsun Inanc ³ , Haluk Kazokoglu ⁴ , Tulin Ergun ⁵ , Haner Direskeneli ³ ¹ Marmara University, Faculty of Health Sciences, Health Management Department, Istanbul, Turkey, ² Marmara University, Faculty of Dentistry, Istanbul, Turkey, ³ Marmara University, School of Medicine, Department of Rheumatology, Istanbul, Turkey, ⁴ Marmara University, School of Medicine, Department of Ophthalmology, Istanbul, Turkey, ⁵ Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey
	019) PAPULOPUSTULAR LESIONS ACCORDING TO AGE, SEX AND BODY PARTS IN BEHCET'S SYNDROME PATIENTS COMPARED HEALTH POPULATIONS AND DISEASED CONTROL Zekayi Kutlubay ¹ , Yesim Ozguler ² , Gulen Hatemi ² , Koray Tascilar ³ , Cem Mat ¹ , Hasan Yazici ² ¹ Cerrahpasa Faculty of Medicine, Department Of Dermatology, Istanbul University, Turkey, ² Cerrahpasa Faculty of Medicine, Department Of Internal Medicine, Division of Rheumatology, Istanbul University, Turkey, ³ Okmeydani Research and Training Hospital, Istanbul, Turkey

17:00 – 17:30	Coffee Break
17:30 - 18:30	Scientific Session 8: Gastrointestinal Disease <i>Chairs: Aykut Ferhat Çelik (Turkey), Ambrogio Orlando (Italy)</i>
17:30 - 17:50	GASTROINTESTINAL MANIFESTATIONS: A CLINICAL OVERVIEW Makoto Naganuma (Japan)
17:50 - 18:20	DIFFERENTIAL DIAGNOSIS Jae Hee Cheon (Korea)
18:20 - 18:30	Oral Presentations
	020) FECAL CALPROTECTIN AS A NON-INVASIVE BIOMARKER FOR INTESTINAL INVOLVEMENT OF BEHÇET'S DISEASE Won Ho Kim, Jae Hee Cheon Yonsei University College of Medicine, Internal Medicine Department, Seoul, Korea
18:30 - 19:00	Scientific Session 9: Paediatric Behçet's Disease <i>Chairs: Seza Özen (Turkey), Marco Gattorno (Italy)</i>
18:30 - 18:50	DIAGNOSIS AND CLASSIFICATION OF PEDBD Isabelle Koné-Paut
18:50 - 19:00	Oral Presentations
	021) BEHÇET DISEASE IN THE PEDIATRIC AGE: DATA ON 129 PATIENTS COLLECTED FROM AN ITALIAN COHORT Romina Gallizzi ¹ , Martina Finetti ² , Mirella Crapanzano ¹ , Luca Cantarini ³ , Marco Cattalini ⁴ , Giovanni Filocamo ⁵ , Antonella Insalaco ⁶ , Angela Mauro ⁷ , Donato Rigante ⁸ , Francesco Zulian ⁹ , Maria Alessio ¹⁰ , Ilaria Parissenti ⁴ , Nicolino Ruperto ² , Marco Gattorno ² , Rolando Cimaz ¹¹ ¹ Policlinico G. Martino, Department of Pediatrics, Messina, Italy, ² Istituto G. Gaslini, Genova, Italy, ³ Policlinico Le Scotte, Siena, Italy, ⁴ Clinica Pediatrica, Brescia, Italy, ⁵ Ospedale Maggiore Clinica II De Marchi, Milano, Italy, ⁶ Ospedale Bambin Gesù, Roma, Italy, ⁷ Seconda Università degli Studi, Napoli, Italy, ⁸ Policlinico Gemelli, Roma, Italy, ⁹ University of Padua, Department for the Woman and Child Health, Padua, Italy, ¹⁰ Policlinico Federico II, Napoli, Italy, ¹¹ Ospedale Meyer, Firenze, Italy
20:30	Social Dinner

● | I CBD 2016 PROGRAMME

17th September 2016, Saturday

- 9:00 - 10:00 **Scientific Session 10: Outcome Measures**
Chairs: Vedat Hamuryudan (Turkey), Dorian Haskard (UK)
- 9:00 - 9:20 **DEVELOPING A CORE SET OF OUTCOME MEASURES FOR CLINICAL TRIALS**
Maarten Boers (Netherlands)
- 9:20 - 9:40 **CHALLENGES IN THE DEVELOPMENT OF OUTCOME MEASURES FOR BD**
Gülen Hatemi (Turkey)
- 9:40 - 10:00 **Oral presentations**
- 022) IMPAIRED QUALITY OF LIFE IN PATIENTS WITH BEHÇET'S DISEASE IS ONLY IN PART RELATED TO DISEASE ACTIVITY**
Matteo Piga, Alberto Floris, Alberto Cauli, Alessandro Mathieu
University Clinic AOU of Cagliari, Department of Rheumatology, Cagliari, Italy
- 023) CORRELATION OF ESR, CRP, AND THE IRAN BEHÇET'S DISEASE DYNAMIC ACTIVITY MEASURE (IBDDAM) IN THE MAJOR MANIFESTATIONS OF BEHÇET'S DISEASE**
Mariam Masoumi, Fereydoun Davatchi, Bahar Sadeghi Abdollahi, Abdolhadi Naji, Farhad Shahram, Cheyda Chams-Davatchi, Massoomeh Akhlaghi, Tahereh Faezi, Hormoz Shams, Zahra Ghodsi, Farimah Ashofteh, Negin Mohtasham, Hoda Kavosi
Tehran University-RRC, Rheumatology Department, Tehran, Iran
- 10:00 - 12:00 **Scientific Session 11: Treatment**
Chairs: Stefano Bombardieri (Italy), Robert Moots (UK)
- 10:00 - 10:20 **ANTI-TNF AND ANTI-IL-1 AGENTS**
Petros Sfikakis (Greece)
- 10:20 - 10:40 **APREMILAST**
Yusuf Yazici (USA)
- 10:40 - 11:00 **INTERFERON**
Ina Kötter (Germany)
- 11:00 - 11:20 **EULAR RECOMMENDATIONS**
Gülen Hatemi (Turkey)

11:20 - 12:00

Oral Presentations

Chairs: Sebahattin Yurdakul (Turkey), Nicolò Pipitone (Italy)

024) EFFECT OF INFLIXIMAB IN CHRONIC PROGRESSIVE BEHÇET'S DISEASE: INFLUENCES OF TIME OF INTRODUCTION ON THE OUTCOME OF THE PATIENTS
Shunsei Hirohata¹, Hirotohi Kikuchi², Tetsuji Sawada³, Masataka Kuwana⁴, Yohei Kirino⁵, Mitsuhiro Takeno⁴, Yoshiaki Ishigatsubo⁵

¹Kitasato University School of Medicine, Department of Rheumatology and Infectious Disease, Sagamihara, Japan, ²Tekkie University School of Medicine, Japan, ³Tokyo Medical University School of Medicine, Tokyo, Japan, ⁴Nippon Medical University Graduate School of Medicine, Tokyo, Japan

025) INFLIXIMAB THERAPY FOR NEUROLOGICAL, VASCULAR, AND INTESTINAL INVOLVEMENT IN BEHÇET'S DISEASE: EFFICACY, SAFETY, AND PHARMACOKINETICS IN A MULTICENTER, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM PHASE 3 STUDY
Yoshiaki Ishigatsubo¹, Shunsei Hirohata², Hirotohi Kikuchi³, Ukihide Tateishi⁴, Noriko Sato⁵, Kunihiko Ozaki⁵, Kazuoki Kondo⁵, Toshifumi Hibi²

¹Yokohama City University Graduate School of Medicine, Yokohama City, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Teikyo University School of Medicine, Tokyo, Japan, ⁴Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan, ⁵Mitsubishi Tanabe Pharma Corporation, Japan

026) EFFICACY AND SAFETY PROFILE OF ANTI-INTERLEUKIN-1 TREATMENT IN BEHÇET'S DISEASE

Luca Cantarini¹, Giacomo Emmi², Sara Talarico³, Giuseppe Lopalco⁴, Rolando Cimaz⁵, Fabrizio Cantini⁶, Ombretta Viapiana⁷, Ignazio Olivieri⁸, Matteo Goldoni⁹, Antonio Vitale¹, Elena Silvestri², Domenico Prisco², Giovanni Lapadula⁴, Florenzo Iannone⁴, Mauro Galeazzi¹

¹University of Siena, Department of Medical Sciences, Surgery and Neuroscience, Siena, Italy, ²University of Florence, Department of Experimental and Clinical Medicine, Florence, Italy, ³University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy, ⁴University of Bari, Interdisciplinary Department of Medicine, Rheumatology Unit, Bari, Italy, ⁵University of Florence and AOU Meyer, Neurofarba Department, Florence, Italy, ⁶Hospital of Prato, Division of Rheumatology, Prato, Italy, ⁷University of Verona, Unit of Rheumatology, Verona, Italy, ⁸San Carlo Hospital of Potenza, Rheumatology Department of Lucania, Potenza, Italy, ⁹University of Parma, Department of Clinical and Experimental Medicine, Parma, Italy

12:00 - 12:30

Closing Remarks


● | I CBD 2016 PROGRAMME

16th September 2016, Friday 8:00 - 9:00

Registration is mandatory at the Desk

“Meet the Expert” Breakfast Session

Pitfalls in the diagnosis of Behçet’s Disease	Fereydoun Davatchi (Iran)
Difficult cases of Vascular Disease	Vedat Hamuryudan (Turkey)
Difficult cases of Ocular Disease	Shigeaki Ohno, Nobuyoshi Kitaichi and Kenichi Namba (Japan)
Difficult cases of Neuro-Behçet’s Disease	Gülşen Akman-Demir (Turkey)
Difficult cases of Mucocutaneous Disease	Giusto Trevisan (Italy)
Difficult cases of Gastrointestinal Disease	Aykut Ferhat Çelik (Turkey)
Difficult cases of Paediatric Disease	Seza Özen (Turkey)
Pregnancy and Behçet’s Disease	Pietro Leccese (Italy)



POSTER PRESENTATION INDEX

Date of Display: 15-16-17.09.2016

BOARD NUMBER	CATEGORY	TITLE
P1	Basic Science	Increased Serum Antibody Titer against HPV-16 Antigen in Patients with Behçet's Disease
P2	Basic Science	IL-27 Gene Polymorphisms in Iranian Patients with Behçet's Disease
P3	Basic Science	Functional analysis of M1 and M2 macrophage in Behçet's disease
P4	Basic Science	Sequencing of 16S rRNA Reveals a Distinct Salivary Microbiome Signature in Behçet's Disease
P5	Basic Science	Increased expression of aryl hydrocarbon receptor in peripheral blood mononuclear cells of patients with active Behçet's disease.
P6	Basic Science	TRIM21 in Monocyte Enhances Th1/Th17 inflammation in Behçet's Disease
P7	Basic Science	The role of CD206 in patients and mouse model of Behçet's disease
P8	Basic Science	Serum lipopolysaccharide levels are associated with disease activity of the oral mucous membrane in Behçet's Disease
P9	Basic Science	CXCL1, CXCR1 and IL-17A
P10	Basic Science	Serum amyloid A stimulated production of pro-inflammatory cytokines by peripheral blood monocytes in patients with Behçet's disease
P11	Basic Science	Increased senescent CD8+ T cells in the peripheral blood mononuclear cells of Behçet's disease patient
P12	Basic Science	IL-17 expression by lymphocytes is higher in Behçet's disease compared to Takayasu's arteritis
P13	Basic Science	A serum metabolomic analysis in Behçet's disease: A preliminary study
P14	Basic Science	Behçet's disease under microbiotic surveillance?
P15	Basic Science	CD16+V 2 T Cells and Their Functional Potential in Behçet's Disease
P16	Basic Science	Differential diagnostic problems in patients with Adamantiades-Behçet's disease
P17	Basic Science	Osteopontin levels and other in ocular Behçet's disease: a controlled study
P18	Epidemiology & Genetics	HLA revisited in Egyptian patients with Behçet's syndrome: New associations of HLA alleles with susceptibility, protection, presentation and severity of the disease.
P19	Epidemiology & Genetics	The North-eastern Asiatic mitochondrial D4j12 clade found in an Italian Behçet's Disease patient: implications in the quantity of genomic traits retained from the Asiatic ancestor.
P20	Epidemiology & Genetics	HLA-B5/51 Genotype: an association with the clinical manifestations of Behçet's disease
P21	Epidemiology & Genetics	Determination of Methylation and Expression of IL-10 Gene in Patients with Behçet's Disease
P22	Epidemiology & Genetics	Transition of clinical manifestation in Japanese Behçet's disease: a retrospective study of 578 patients
P23	Epidemiology & Genetics	Association of genetic polymorphisms in Interferon- γ , Interleukin-6 and transforming growth factor- β 1 gene with Behçet's disease susceptibility
P24	Epidemiology & Genetics	The prevalence of Behçet's disease in north Jordan
P25	Epidemiology & Genetics	Ocular Behçet's disease is less complicated with allergic disorders – a nationwide survey in Japan
P26	Epidemiology & Genetics	Association study of TRAF5 and TRAF3IP2 gene polymorphisms with susceptibility to Behçet's disease and Vogt-Koyanagi-Harada disease in a Japanese population
P27	Epidemiology & Genetics	Prevalence of Behçet's Disease and other uveitic conditions in secondary eye care: A preliminary study
P28	Epidemiology & Genetics	Behçet's Disease: ethnos and familial aggregation
P29	Epidemiology & Genetics	The correlation of prefectural prevalence of Behçet's disease with cigarette smoking rate in Japan.
P30	Epidemiology & Genetics	British Paediatric Surveillance Unit (BPSU) study of Behçet's syndrome in children and young people in the United Kingdom
P31	Epidemiology & Genetics	Articular manifestation of Behçet's Disease in northern Italy
P32	Epidemiology & Genetics	A Darwinian view of behçet's Disease
P33	Epidemiology & Genetics	Importance of less sensitive features to increase probabilities of Behçet's Disease diagnosis
P34	Epidemiology & Genetics	Behçet's Syndrome Associated with Takayasu's Arteritis: A Case Series of 10 Patients
P35	Epidemiology & Genetics	An Italian familial case of Behçet's Disease after Varicella Zoster Virus infection
P36	Epidemiology & Genetics	Mean Platelet Volume as a Biomarker Representing Clinical Activity and Treatment Response in Behçet's Disease
P37	Epidemiology & Genetics	Genotyping a panel of gene variations related to Behçet's disease: a preliminary Italian study

P38	Epidemiology & Genetics	Investigating the mutational state of ERAP1 gene: the identification of known and novel single nucleotide polymorphisms (SNPs) in a cohort of Italian Behçet's disease patients
P39	Clinical and Outcome Measures	Elevated serum prolactin in Egyptian patients with Behçet's syndrome
P40	Clinical and Outcome Measures	Allergic reaction to oral bacteria in patients with Behçet's disease and the related diseases
P41	Clinical and Outcome Measures	The assessment of work productivity and activity impairment in Behçet's disease
P42	Clinical and Outcome Measures	Illness perception in patients with Behçet disease: emotional reactions to disease symptoms
P43	Clinical and Outcome Measures	Pathergy test in Behçet's Disease: Diagnostic or Prognostic?
P44	Clinical and Outcome Measures	Subfoveal choroidal thickness as an indicator of subclinical ocular and systemic inflammation in eyes with Behçet's disease without active ocular inflammation
P45	Clinical and Outcome Measures	The comparison of Mental Disorders in Behçet's Disease and Rheumatoid Arthritis patients
P46	Clinical and Outcome Measures	Efficacy and Safety of Infliximab and Cyclosporine Combination Therapy for Uveoretinitis in Behçet's Disease
P47	Clinical and Outcome Measures	Serum lipopolysaccharide levels are associated with disease activity of the oral mucous membrane in Behçet's Disease.
P48	Clinical and Outcome Measures	Comparison of Spectral Domain Optical Coherence Tomography (SD-OCT) findings and laser flare photometry (LFP) levels in Behçet uveitis.
P49	Clinical and Outcome Measures	Establishing a National Service for Behçet's Syndrome in the UK – experience of the first four years
P50	Clinical and Outcome Measures	Pulmonary embolism in Behçet: Particularities
P51	Clinical and Outcome Measures	Atypical neurological manifestations in Behçet's disease: 40 cases
P52	Clinical and Outcome Measures	Oral health related outcome measures, mucocutaneous index and OHIP-14, correlate well with the clinical assesment of oral ulcers in BD
P53	Clinical and Outcome Measures	Clinical significance of serum YKL-40 in Behçet's disease
P54	Clinical and Outcome Measures	Application ICBD criteria in tunisian population
P55	Clinical and Outcome Measures	Comparison of deep venous thrombosis associated with Behçet's disease to idiopathic deep venous thrombosis
P56	Clinical and Outcome Measures	Evolution of demographic and clinical features of Behçet's disease in Tunisia
P57	Clinical and Outcome Measures	Arterial aneurysms complicating Behçet's disease
P58	Clinical and Outcome Measures	A pseudotumor revealing bladder vasculitis
P59	Clinical and Outcome Measures	Clinical characteristics of late onset Behçet's disease
P60	Clinical and Outcome Measures	Effects of gender on the clinical features of Behçet's disease
P61	Clinical and Outcome Measures	Budd-Chiari syndrome in Behçet disease: Moroccan experience
P62	Clinical and Outcome Measures	Baseline endothelial dysfunction might predict immunosuppressive need in young, male Behçet's patients with early disease: a prospective follow-up
P63	Clinical and Outcome Measures	Relationship between menstruation and symptoms of Behçet's syndrome
P64	Clinical and Outcome Measures	The difference between international criteria for BD (ICBD) and the BD criteria of international study group (ISG) in our Behçet's disease (BD) patients who fulfilled Japanese BD criteria

POSTER PRESENTATION INDEX

Date of Display: 15-16-17.09.2016

P65	Clinical and Outcome Measures	Outer Plexiform Layer Elevation as a Surrogate Marker for History of Posterior Ocular Attacks in Behcet's Disease
P66	Clinical and Outcome Measures	Acute- and chronic progressive-type neuro-Behçet's disease: Investigation of 2 cases
P67	Clinical and Outcome Measures	Development of a multi-disciplinary service for children and young people with Behçet's syndrome
P68	Clinical and Outcome Measures	Superior and inferior vena cava thrombosis: outcome after introduction by immunosuppressive agent in morocco.
P69	Clinical and Outcome Measures	Acute myocarditis revealing Behçet's Disease
P70	Clinical and Outcome Measures	Associated malignancy in Behçet disease
P71	Clinical and Outcome Measures	Vascular involvement in Behçet disease in the Tunisian context
P72	Clinical and Outcome Measures	Hughes Stovin Syndrome revealing Behçet Disease
P73	Clinical and Outcome Measures	Venous Quality of Life Does not Change in Follow up in Patients with Vascular Behçet's Disease
P74	Clinical and Outcome Measures	Vitamin D Status and Behcet's disease in the Midwest region in Ireland
P75	Clinical and Outcome Measures	A subgroup analysis of comorbidities in Behçet's Disease; results from a prospective case-controlled study
P76	Clinical and Outcome Measures	Development of a Patient Concerns Inventory for Behçet's Disease
P77	Clinical and Outcome Measures	Coronary Artery Disease in Patients with Behçet's Disease: A retrospective, single center study
P78	Clinical and Outcome Measures	Low medication adherence is associated with oral ulcer activity and quality of life in Behçet's disease
P79	Clinical and Outcome Measures	An exemplar Behçet case, in all its multisystemic features
P80	Clinical and Outcome Measures	Disease characteristics of Behçet's disease among filipino patients seen in rheumatology clinics
P81	Clinical and Outcome Measures	Interferon- release assay (T-SPOT.TB) in the diagnosis of tuberculosis infection in patients with Behcet's disease: a single center experience in China
P82	Clinical and Outcome Measures	Identifying Core Domains for Behçet's Syndrome Trials: An International Physician and Patient Delphi Exercise
P83	Clinical and Outcome Measures	Fecal Calprotectin Level Looks Promising in Identifying Active Disease in Behçet's Syndrome Patients with
P84	Clinical and Outcome Measures	A Behçet's disease patient with percardial tamponade related to right coronary pseudoaneurysm.
P85	Clinical and Outcome Measures	A Systematic Literature Review on the Treatment of Major Organ Involvement of Behçet's Syndrome Informing the EULAR Recommendations for the Management of Behçet's Syndrome
P86	Clinical and Outcome Measures	Multiple coagulation disorders- thrombophilia and antiphospholipid syndrome-in a patient with Behcet's Disease
P87	Clinical and Outcome Measures	PET/CT Imaging In Patients With Vascular Behçet's Disease
P88	Clinical and Outcome Measures	Transverse Myelitis – Neuro-Behcet's onset
P89	Clinical and Outcome Measures	Clinical features and treatment choices in Behcet's Disease patients
P90	Clinical and Outcome Measures	The vestibular involvement in Behçet's disease: a cross-sectional study
P91	Clinical and Outcome Measures	Mean platelet voume as a biomarker representing treatment response in Behcet's disease

P92	Clinical and Outcome Measures	Evaluation of Children with Behçet's Disease from Regionally Two Different Centers of a Highly Prevalent Country.
P93	Clinical and Outcome Measures	Evaluation of cognitive function electrophysiologically in children with Behçet's disease
P94	Clinical and Outcome Measures	Comparative study of clinical characteristics in Tunisian patients with Behçet Disease with or without associated ocular involvement.
P95	Clinical and Outcome Measures	Markers of Systemic Inflammation in Behçet's Syndrome
P96	Clinical and Outcome Measures	Neutrophil to lymphocyte ratio and mean platelet volume and Behçet disease activity
P97	Clinical and Outcome Measures	Pseudotumoral Neuro behçet: 4 cases
P98	Clinical and Outcome Measures	The significance of nonoral-aphthous beginning and preaphthous phase of Behçet disease on the diagnosis and prognosis: a comparative study with the world literature
P99	Clinical and Outcome Measures	A systematic literature review on the treatment of skin, mucosa and joint involvement of Behçet's syndrome informing the eular recommendations for the management of Behçet's syndrome
P100	Clinical and Outcome Measures	Brain 18F-FDG PET/CT abnormalities in Neuro-Behçet's Disease
P101	Clinical and Outcome Measures	Prevalence of Type 2 Diabetes in Behçet's Disease: a retrospective study
P102	Clinical and Outcome Measures	Familial Behçet's Disease: a report of 2 cases from an Italian Behçet Family
P103	Treatment	Persistent hyperprolactinemia during therapy with interferon- 2a in a patient with systemic Adamantiades-Behçet's disease
P104	Treatment	Complete resolution of pulmonary artery aneurysm in a patient with Behcet's disease with infliximab
P105	Treatment	Plasma cytokines as biomarkers for clinical response during nine months of Intravenous Immunoglobulins therapy in a Behçet's Disease patient unsuitable for immunosuppression
P106	Treatment	Systematic review of the literature for the use of Intravenous Immunoglobulins in Behçet's Disease
P107	Treatment	Outcomes of biologic treatment regimens for severe Behcet's disease: current experience from a single academic center
P108	Treatment	The efficacy of tacrolimus against intestinal Behcet's disease
P109	Treatment	Benzathine Penicillin in Treatment of Oral and Genital Ulcers in Behcet's Disease
P110	Treatment	Anti-TNF- Therapy in Patients with Behçet's Uveitis
P111	Treatment	Behcet's disease in Ireland: Patient Access and Response to Anti-TNF Biologics
P112	Treatment	Aneurysmal Arterial Disease requiring surgical intervention in Behcets: A Case Series
P113	Treatment	Interferon Alfa-2a in Treatment of Refractory Uveitis associated Behçet's Disease: A Single-Centre Experience in China
P114	Treatment	Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement
P115	Treatment	Apremilast for the treatment of Behcet's syndrome: Routine care, real world experience
P116	Treatment	Deep abdominal wall ulceration in a Admantiades-Behcet's Disease patient
P117	Treatment	Behçet's disease in a patient with vertically transmitted HIV infection succesfully treated with ANTI TNF-ALFA therapy- a case report and systematic literature review
P118	Treatment	The effect of medication on the treatment outcomes of Behçet Disease
P119	Treatment	Certolizumab Pegol Treatment in Behcet's Disease: a Multicenter Retrospective Observational Study
P120	Treatment	Surgical method for aortic root involvement of Behçet's Disease
P121	Treatment	The efficacy and safety of anti-TNF- in Behçet's Disease: a case series
P122	Treatment	Ustekinumabefficacy inrefractory Behçet's Disease
P123	Clinical and Outcome Measures	A case of Behcet's Disease presenting with deep venous thrombosis.
P124	Basic Science	Immunological profiling of aqueous humor in Behçet's Disease patients with active ocular involvement
P125	Treatment	Effective and rapid treatment of flares in patients with Behçet's Disease by the single chain anti-tnf antibody dlx105

● **INTERNATIONAL PATIENTS’
CONFERENCE-MATERA 2016**
Conference Venue: **Palace Hotel p.zza Michele Bianco**

Saturday, 17th September 2016 -

- 8.50-17.30 Patients’ Conference
Chairs: Alessandra Del Bianco (Italy), Richard West (UK)
- 8.50-9.00 Welcome
Ignazio Olivieri (Italy)
- 9.00-9.40 **GENETICS AND PATHOGENESIS**
Haner Direskeneli (Turkey)
- 9.40-10.20 **PSYCHOLOGICAL ASPECTS**
Giacomo Belcari (Italy)
- 10.25-11.05 **FERTILITY, CONTRACEPTION AND PREGNANCY**
Pietro Leccese (Italy)
- 11.05-11.30 Coffee break
- 11.30-12.10 **BEHÇET’S DISEASE IN CHILDREN**
Isabelle Koné-Paut (France)
- 12.15-12.55 **NEURO-BEHÇET’S DISEASE**
Adnan Al-Araji (UK)
- 12.55-14.00 Lunch
- 14.00-14.40 **OCULAR DISEASE**
Shigeaki Ohno (Japan)
- 14.45-15.25 **MUCOCUTANEOUS DISEASE**
Farida Fortune (UK)
- 15.30-16.10 **TREATMENT**
Hasan Yazici (Turkey)
- 16.10-16.30 Coffee Break
- 16.30-16.45 **HIGHLIGHTS OF THE CONFERENCE**
Ahmet Gül (Turkey)
Gulen Hatemi (Turkey)
- 16.45-17.30 Patients’ Association and future conferences



● | SOCIAL PROGRAMME

15th September 2016 - (FREE FOR PARTICIPANTS)

ORE 19.30 Concert at Auditorium R. Gervasio, Piazza del Sedile, Matera

Antonio Vivaldi LE QUATTRO STAGIONI

Organic

Stefano Montanari *violin soloist*

Baroque orchestra with original instruments

LA CONFRATERNITA DE' MUSICI

Cosimo Prontera *Organ and harpsichord direction*

Main violin Raffaele Tiseo *first violins* Giovanni Rota, Cristiano Brunella

Second violins Laura Scipione, Pierpaolo Del Prete, Domenico Nisi

Violas Pasquale Lepore, Emanuele Marcante

Cellos Claudio Mastrangelo, Gianlorenzo Sarno

Double basses Maurizio Ria

Theorbo Michele Carreca

16th September 2016 - (TICKET WIL BE REQUESTED)

Palazzo Bernardini

ORE 20:30 Social Dinner

PALAZZO BERNARDINI

Palazzo Bernardini is an historical house located in Piazza del Sedile, in the heart of the historic center of Matera. The palace overlooks the Sassi di Matera and represents one of the rare examples in the Basilicata region of historic home of a patrician family, Ferrau, which still retains a significant part of the furnishings and original decorative elements dating from the end of 1700 and 1802.

It is a building which was built around 1448 and includes a private house, currently under constraint for its historic and artistic value, made up of 17 rooms mostly frescoed and among which stands out the "party room or tunnel" that is decorated and full of original furnishings.



SOCIAL PROGRAMME FOR ACCOMPANYING PERSON

Thursday, 15th September, 2016 - (TICKET WIL BE REQUESTED)




Guided tour of Matera: "Sassi" itinerary

A walking tour in a unique site in the world, declared Unesco World Heritage Site in 1993 and also a natural set of several international movies, among which "Il Vangelo secondo Matteo" in 1964, "The Passion" in 2004, "Ben Hur" in 2015 and many others. Visitors, accompanied by a specialised tourist guide into the characteristic "Sassi" district ("Sasso Barisano and Sasso Caveoso"), will be able to relive distant emotions, absorbed in a landscape beyond time. The itinerary is marked by follow-up breaks and a visit to the "Casa Grotta" is expected, to better understand habits and customs of the ancient district's inhabitants.

Departure time: 10.00 am from the Congress Venue

Maximum 30 participants

Friday, 16th September, 2016 - (TICKET WIL BE REQUESTED)



Guided tour of the "Piano", between Baroque and Romanesque styles, and guided tour of the "Palombaro Lungo"

The itinerary starts from the area called "il Piano", an urban area above the "Sassi", characterised by alleys, streets and staircases full of workshops. In the city centre it will be possible to admire the several churches built in Baroque and Romanesque styles, among which the Cathedral, built in Apulian-Romanesque style in the XIII century. It is located in the part of the city known as the Civita, which was the first inhabited nucleus of the Sassi, in the highest and most prominent part of the city that divides the two "Sassi". Its restoration has been completed in 2016. At the end of the tour a break is provided to allow participants to visit the "Palombaro Lungo", built in the nineteenth century as a part of the water system.

Departure time: 10.00 am from the Congress Venue

Maximum 30 participants

● | SOCIAL PROGRAMME

Saturday, 17th September, 2016 - (TICKET WIL BE REQUESTED)



Guided tour of the archaeological historical and natural park of rupestrian churches

A tour of the suggestive "Murgia Timone", into the archaeological historical and natural park of rupestrian churches. The upland, that dominates the massif placed toward East, is located in front of the Civita, the ancient Matera's city centre, where you can enjoy the best view of the city. Here it will be possible to discover the beauties of this area, starting from Neolithic, with its "Villaggio Trincerato", ending the tour with a visit of several rupestrian churches.

Departure time: 10.00 am from the Congress Venue
Maximum 30 participants

SOCIAL PROGRAMME FOR PARTICIPANTS

Saturday, 17th September, 2016 - (FREE FOR PARTICIPANTS)



Guided tour of Matera

A walking tour in a unique site in the world, declared Unesco World Heritage Site in 1993 and also a natural set of several international movies, among which "Il Vangelo secondo Matteo" in 1964, "The Passion" in 2004, "Ben Hur" in 2015 and many others. The itinerary starts from the area called "il Piano", an urban area above the "Sassi", characterised by alleys, streets and staircases full of workshops, to flow then into the characteristic districts called "Sassi" ("Sasso Barisano" and "Sasso Caveoso") where it will be possible to relieve distant emotions, absorbed in a landscape beyond time. The itinerary is marked by follow-up breaks and visits.

Departure time: 3.00 pm from the Congress Venue
Maximum 80 participants



under the patronage of



Provincia
di Potenza



REGIONE BASILICATA



APT BASILICATA



PROVINCIA DI MATERA



AZIENDA OSPEDALIERA REGIONALE
S. CARLO
OSPEDALE "SAN CARLO" DI POTENZA
OSPEDALE "SAN FRANCESCO DI PAOLA" DI PESCOFAGANO



COMUNE DI MATERA



ORDINE PROVINCIALE
DEI MEDICI CHIRURGI
E DEGLI ODONTOIATRI
P O T E N Z A



17th INTERNATIONAL CONFERENCE ON BEHÇET'S DISEASE

MATERA

15th - 17th SEPTEMBER 2016

CONGRESS SECRETARIAT

Allmeetings

Via Passarelli 137/bis -75100 - Matera

phone/fax. +39 0835 256592

mobile +39 392 9895516

segreteria@allmeetingsmaterait

www.allmeetingsmaterait